TY - JOUR
T1 - Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status
AU - Huh, Ji Hye
AU - Kim, Kwang Joon
AU - Kim, Seung Up
AU - Han, Seung Hwan
AU - Han, Kwang Hyub
AU - Cha, Bong Soo
AU - Chung, Choon Hee
AU - Lee, Byung Wan
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Objective The pathogenesis of non-alcoholic fatty liver disease (NAFLD) involves multiple concomitant events induced by obesity and metabolic health condition. This study aimed to assess the risk of NAFLD according to metabolic health and obesity status using transient elastography (TE). Materials and Methods A total of 2198 asymptomatic adults without chronic liver disease and who underwent a medical health check-up were recruited. Subjects were categorized into four groups according to metabolic health and obesity statuses: metabolically healthy non-obese (MHNO); metabolically unhealthy non-obese (MUNO); metabolically healthy obese (MHO); and metabolically unhealthy obese (MUO). Hepatic steatosis was defined as controlled attenuation parameter (CAP) ≥ 238 dB/m, and significant liver fibrosis was defined as liver stiffness measurement (LSM) > 7.0 kPa, as defined by TE. Results Compared with MHNO group, the odds ratios (ORs) [95% confidence interval (CI)] for hepatic steatosis were 2.94 [2.32–3.71], 4.62 [3.52–6.07], and 12.02 [9.08–15.92] in the MUNO, MHO, and MUO groups, respectively (P < 0.001) in crude model. Regarding liver fibrosis, there was no significant difference in the ORs in MUNO group (ORs: 0.95 [95% CI, 0.33–2.78], P value = 0.929), whereas there was a significant increase in the ORs in MHO group compared with MHNO group (ORs: 4.32 [95% CI, 1.73–10.76], P = 0.002) in the fully adjusted model. Conclusion Our results show that MHO was associated with both liver steatosis and fibrosis assessed by transient elastography. Our results suggest that a healthy metabolic profile does not protect obese adults from hepatic steatosis or fibrosis, indicating that obesity itself might contribute to liver fibrosis.
AB - Objective The pathogenesis of non-alcoholic fatty liver disease (NAFLD) involves multiple concomitant events induced by obesity and metabolic health condition. This study aimed to assess the risk of NAFLD according to metabolic health and obesity status using transient elastography (TE). Materials and Methods A total of 2198 asymptomatic adults without chronic liver disease and who underwent a medical health check-up were recruited. Subjects were categorized into four groups according to metabolic health and obesity statuses: metabolically healthy non-obese (MHNO); metabolically unhealthy non-obese (MUNO); metabolically healthy obese (MHO); and metabolically unhealthy obese (MUO). Hepatic steatosis was defined as controlled attenuation parameter (CAP) ≥ 238 dB/m, and significant liver fibrosis was defined as liver stiffness measurement (LSM) > 7.0 kPa, as defined by TE. Results Compared with MHNO group, the odds ratios (ORs) [95% confidence interval (CI)] for hepatic steatosis were 2.94 [2.32–3.71], 4.62 [3.52–6.07], and 12.02 [9.08–15.92] in the MUNO, MHO, and MUO groups, respectively (P < 0.001) in crude model. Regarding liver fibrosis, there was no significant difference in the ORs in MUNO group (ORs: 0.95 [95% CI, 0.33–2.78], P value = 0.929), whereas there was a significant increase in the ORs in MHO group compared with MHNO group (ORs: 4.32 [95% CI, 1.73–10.76], P = 0.002) in the fully adjusted model. Conclusion Our results show that MHO was associated with both liver steatosis and fibrosis assessed by transient elastography. Our results suggest that a healthy metabolic profile does not protect obese adults from hepatic steatosis or fibrosis, indicating that obesity itself might contribute to liver fibrosis.
KW - Liver fibrosis
KW - Metabolically healthy obese
KW - Non-alcoholic fatty liver disease
KW - Transient elastography
UR - http://www.scopus.com/inward/record.url?scp=84994589962&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994589962&partnerID=8YFLogxK
U2 - 10.1016/j.metabol.2016.10.003
DO - 10.1016/j.metabol.2016.10.003
M3 - Article
C2 - 27923446
AN - SCOPUS:84994589962
SN - 0026-0495
VL - 66
SP - 23
EP - 31
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
ER -